Hirva Mandani, MD

Paul Nguyen, MD

Meghan Mooradian, MD

Liao Zhongxing, MD

Howard Scher, MD

Scott Perlman, MD

Mary Pat Berry

George Wilding, MD

George Wilding, MD, graduated with an MD from the University of Massachusetts Medical School where he also trained in Internal Medicine. He received training in Medical Oncology in the Medicine Branch at the NCI. He served on the faculty of the University of Wisconsin-Madison from 1988 to 2015. His research focused in the laboratory and clinic on prostate carcinogenesis and the development of new therapies for advanced prostate cancer.

During his time at the University of Wisconsin, he served as the Head of Hematology/Oncology for 18 years and as Director of the Carbone Cancer Center, an NCI designated comprehensive cancer center, for approximately 12 years. From September 2015 to February 2020, Dr. Wilding served as Vice President and Vice Provost/Deputy Chief Academic Officer of Clinical and Interdisciplinary Research at The University of Texas MD Anderson Cancer Center. From September 2015 to January 2021, he served as a Professor of Genitourinary Medical Oncology and Associate Director for Interdisciplinary Research on the NCI Cancer Center Support Grant for MD Anderson.

He was also part of the Moon Shot Leadership Team and was active in the Global Academic Program with activities in Poland, Hungary, China and Mexico. Upon retirement from MD Anderson in January 2021, he continues as an external advisor to the MDA Sabin Fellowship, the Moon Shot Program and the GU Medical Oncology Research Program. He also continues to be engaged in international programs, such as the Medical Research Agency Advisory Council of the Polish Health Ministry and scientific advisory activities internationally and nationally.

Eric Liu, MD

Dr. Eric Liu is a board-certified general surgeon with advanced sub-specialty expertise in neuroendocrine cancers. He is a recognized leader in multi-modal treatment of neuroendocrine tumors and, specifically, in the use of theranostics. He was the first investigator in the United States to perform the 68-Gallium-DOTATATE PET/CT scan for neuroendocrine tumors. He is an invited speaker both nationally and internationally and contributes to national treatment guidelines.

Dr. Liu was educated at Harvard and Columbia Universities and trained in surgery at New York-Presbyterian Hospital. He developed a specialty neuroendocrine center at Vanderbilt University in Nashville, where he was assistant professor of surgery and radiology, before moving to Colorado to establish the Neuroendocrine Institute at Rocky Mountain Cancer Centers in2015. He is the co-founder of the Healing NET Foundation, a 501c3 charitable organization that supports education and advocacy for neuroendocrine tumors.

Australian Privacy Policy AIQ's software has been cleared for clinical use under 510(k) K173444. For details, including the applicable Indications for Use, see: